A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Eligibility Criteria

• 1. Participants with Progressive forms of Multiple Sclerosis including Primary Progressive and Secondary Progressive MS.
• 2. Participants must have discontinued disease modifying therapy (DMT) prior to signing the ICF and meet the following washout criteria prior to receiving lymphodepletion.
• 1. History of malignancy that has not been in remission for at least 2 years.
• 2. Viral Screening
• 1. Evidence of chronic active or history of hepatitis B virus (HBV).
• 2. Seropositive for human immunodeficiency virus (HIV) antibody.
• 3. History of bone marrow/hematopoietic stem cell or solid organ transplantation.
• 4. Prior treatment with adoptive T-cell therapy or any gene therapy product directed at any target (e.g. CAR T-cell therapy).